Clinical trial

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

NCT01333358

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2011-05-01

PhasePHASE3

Study timeline

Study start (unknown)2011-05-01Date precision: month

Registry last updated2011-04-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

AlemtuzumabDRUG · verified · RxNorm: alemtuzumab

Sponsors & collaborators

Central Texas Neurology Consultantslead sponsor

Genzyme, a Sanofi Companycollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01333358 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.